Skip to main content
letter
. 2019 Oct 8;34(3):938–941. doi: 10.1038/s41375-019-0587-5

Fig. 2.

Fig. 2

DNMTi treatment shows additive effect with ATRA in ADCC assays. Results from ADCC assays with azacytidine (a) and decitabine (b). Cell lysis is depicted on the y-axis with increasing concentrations of daratumumab (x-axis). The percent lysis by ADCC was calculated as outlined in the Methods section. Colors indicate the treatments, and fold change in CD38 MFI are given in brackets (red). Depicted is one representative experiment from two independent experiments. The p-values at 10 ug/ml concentration are given below in the table. Asterisk indicates a significant difference (p ≤ 0.05) and NS indicates p > 0.05 (paired student’s t-test)